ReviewMolecular cancer therapeutics2022

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors.

Jacob J Adashek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.